Milk Thistle

Metadata

• Common Names: Milk Thistle, St. Mary’s Thistle (English); Mariendistel (German)
• Botanical Name: Silybum marianum (L.) Gaertn.
• Plant Family: Asteraceae (Compositae)
• Part Used: Ripe fruit/seed (Silybi mariani fructus)
• Evidence Quality Rating: Moderate (hepatoprotective mechanism well-characterized; clinical outcome data mixed)

Approved Indications

Commission E

• Toxic liver damage
• Supportive treatment for chronic inflammatory liver conditions
• Hepatic cirrhosis (supportive)
• Dyspeptic complaints (minor indication)

ESCOP

• Toxic liver damage (e.g., from Amanita phalloides mushroom poisoning)
• Supportive treatment in chronic inflammatory liver disease
• Hepatic cirrhosis
• Supporting treatment of patients with chronic inflammatory liver conditions and cirrhosis of the liver

EMA/HMPC

• Well-established use: None formally designated (insufficient clinical evidence for this classification)
• Traditional use: Relief of digestive complaints such as sensation of fullness, dyspepsia, bloating, and flatulence
• The EMA noted that while pharmacological and preliminary clinical data support hepatoprotective properties, the clinical evidence was deemed insufficient to classify liver indications as “well-established use”

Agreement/Disagreement Between Bodies

• Commission E and ESCOP agree on hepatoprotective / liver support indications
• The EMA/HMPC is notably more conservative: declined to grant well-established use for liver indications, restricting the traditional use monograph to digestive complaints only
• This represents a significant divergence: Commission E/ESCOP endorse liver protection while EMA does not formally support it at the “well-established” level
• All bodies acknowledge safety and tolerability

Conditions Treated

• Toxic liver damage (Amanita phalloides poisoning)
• Chronic hepatitis (B, C)
• Alcoholic liver disease
• Non-alcoholic fatty liver disease (NAFLD/NASH)
• Drug-induced hepatotoxicity
• Hepatic cirrhosis (supportive)
• Dyspeptic complaints (minor indication)
• Chemotherapy-related hepatotoxicity (emerging indication)

Mechanism of Action

• Silymarin (standardized extract containing 65-80% flavonolignans): Mixture of four major isomers:
  • Silybin (silibinin) — most active and most abundant (50-60% of silymarin)
  • Silychristin (~20%)
  • Silydianin (~10%)
  • Isosilybin (~5%)
• Antioxidant activity: Scavenges free radicals; inhibits lipid peroxidation; increases intracellular glutathione concentrations by 35%
• Membrane stabilization: Modifies hepatocyte outer membrane structure, preventing penetration of hepatotoxins (e.g., amatoxin, phalloidin)
• Enhanced protein synthesis: Stimulates ribosomal RNA polymerase I in hepatocytes, promoting liver cell regeneration
• Anti-inflammatory: Inhibits NF-kB pathway; reduces TNF-alpha and IL-6 production in liver tissue
• Antifibrotic: Inhibits hepatic stellate cell activation and collagen deposition; downregulates profibrogenic factors (TGF-beta1)
• Choleretic: Mild bile flow stimulation
• Insulin sensitizing: Emerging evidence for improvement of insulin resistance in NAFLD (may reduce HbA1c)

Clinical Evidence Summary

Cochrane Systematic Review (2007, updated 2012)

• 13 RCTs with 915 patients with alcoholic and/or hepatitis B or C liver diseases
• No significant effects on all-cause mortality, complications of liver disease, or liver histology
• Conclusion: “No evidence supporting or refuting milk thistle for alcoholic and/or hepatitis B or C virus liver diseases”
• Significant methodological limitations in included trials noted

AHRQ Evidence Report (2000)

• Reviewed 16 clinical trials
• “Milk thistle was associated with significantly lower liver-related mortality in trials involving patients with liver disease, but these data are difficult to interpret given the heterogeneity of the studies”

NAFLD/NASH — More Promising

• Systematic review and meta-analysis (2024): Silymarin significantly reduced ALT and AST levels in NAFLD/NASH patients; liver histology showed improved hepatic steatosis in intervention groups
• Multiple trials (n=50-200 per trial) show consistent biochemical improvement (liver enzymes) though not always histological improvement

SyNCH Trial (JAMA, 2012)

• Large RCT (n=154): Silymarin (420mg or 700mg three times daily) vs placebo in hepatitis C patients who failed interferon therapy
• Neither dose achieved significant reduction in serum ALT compared to placebo at 24 weeks
• Raised questions about bioavailability and adequate dosing

Amanita Phalloides Poisoning

• Intravenous silibinin (Legalon SIL) is used as an emergency antidote for Amanita mushroom poisoning in European hospitals
• Retrospective analyses suggest reduced mortality from ~30% to ~10% when administered within 48 hours
• This remains one of the strongest clinical applications, though RCTs are ethically difficult

Biochemical Improvements

• Systematic review (World J Gastroenterol, 2017): Silymarin significantly reduced ALT and AST across multiple liver disease etiologies
• Systematic review (PMC, 2023): Impact on liver enzyme levels confirmed across multiple studies

European vs US/Anglophone Consensus

• Major divergence: In Germany, milk thistle is a legitimate hepatoprotective prescribed by physicians and covered by some insurance plans; standardized silymarin extracts (Legalon, Siliphos) are pharmacy products
• In the US, milk thistle is classified as a dietary supplement with no FDA-approved indications
• The AHRQ and NCCIH acknowledge potential but note insufficient evidence for definitive claims
• European physicians commonly use milk thistle for drug-induced liver injury prevention and as supportive therapy in chronic liver disease
• US hepatologists generally do not recommend milk thistle, citing Cochrane review conclusions
• The bioavailability problem (silymarin is poorly absorbed orally) is a recognized challenge; newer phytosome formulations (e.g., Siliphos/Indena) aim to improve this
• IV silibinin for Amanita poisoning is available in Europe but has limited availability in the US (available through emergency IND)

Safety Profile

Contraindications

• Known allergy to Asteraceae/Compositae family
• Hormone-sensitive conditions (breast, uterine, ovarian, prostate cancer; endometriosis; uterine fibroids) — silymarin may exhibit weak estrogenic activity

Drug Interactions

• CYP enzyme effects: Conflicting data; in vitro studies suggest inhibition of CYP3A4, CYP2C9, and UGT enzymes, but most clinical pharmacokinetic studies show no significant effects on CYP1A2, CYP2C9, CYP2D6, or CYP3A4/5 at usual doses
• Caution with narrow therapeutic window drugs: Warfarin, cyclosporine, indinavir, metronidazole — theoretical interaction potential
• Metformin: Potential synergistic glucose-lowering effect
• Chemotherapy: Mixed data — some evidence of protective effect on hepatotoxicity without reducing anticancer efficacy; consult oncologist

Side Effects

• Generally very well tolerated (one of the safest herbal medicines)
• Mild GI complaints: nausea, diarrhea, bloating (2-10% incidence)
• Headache (uncommon)
• Pruritus (rare)
• Allergic reactions (very rare)
• Safe at doses up to 700 mg three times daily for 24 weeks in clinical trials

Pregnancy/Lactation

• One clinical trial demonstrated safety in pregnancy with no anomalies
• Traditionally used to promote lactation (galactagogue)
• Insufficient data for definitive safety declaration; European authorities advise caution
• Compatible with breastfeeding per some European sources; LactMed notes insufficient data

Clinical Dosage

Forms and Ranges

• Standardized extract (70-80% silymarin): 140 mg three times daily (420 mg/day total) — most common clinical dose
• Higher dose: 200-400 mg silymarin three times daily (used in some clinical trials for hepatitis C)
• Duration: Minimum 8-12 weeks for chronic conditions; may be continued long-term
• Phytosome formulation (Siliphos): 120-240 mg silybin phytosome twice daily (improved bioavailability — up to 4.6x higher absorption)
• IV Silibinin (Legalon SIL): 20-50 mg/kg/day IV infusion for acute Amanita poisoning (hospital setting only)

Key Standardized Products

• Legalon (Madaus/Rottapharm): Standardized silymarin extract; most studied branded product in Europe
• Legalon SIL: IV silibinin for acute liver failure/Amanita poisoning
• Siliphos (Indena): Silybin-phosphatidylcholine phytosome complex for enhanced bioavailability
• Thisilyn (Nature’s Way): US market standardized milk thistle
• Milk thistle fruit per European Pharmacopoeia: minimum 1.5% silymarin (calculated as silybin)

Sources

• EMA/HMPC Assessment Report on Silybum marianum (L.) Gaertn., fructus
• Commission E Monograph: Silybi mariani fructus
• ESCOP Monograph: Silybi mariani fructus
• Rambaldi A, et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases. Cochrane Database Syst Rev. 2007;(4):CD003620 (updated 2012)
• Fried MW, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C. JAMA. 2012;308(3):274-282
• AHRQ Evidence Report: Milk Thistle: Effects on Liver Disease and Cirrhosis. 2000
• Abenavoli L, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423-1432
• Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplement Med. 2008;15:9-20
• Zhong S, et al. Effect of silymarin on biochemical indicators in patients with liver disease. World J Gastroenterol. 2017;23(27):5004-5013

Connections

• Related to Artichoke as hepatoprotective agents in the European phytotherapy tradition
• Milk thistle fruit is a component of STW 5/Iberogast
• Compare with the Cochrane-level evidence challenges shared by many herbs in this collection
• The bioavailability challenge is a cross-cutting theme relevant to herbal medicine generally